Share
    NEW SEARCH RETURN TO SEARCH RESULTS
Number: 201108327 Principal Investigator: Wang-Gillam, Andrea
Title: Phase I Study of Erlotinib and Temsirolimus in Resistant Solid Malignancies
Phase: I Disease Site: Multiple Sites
Participating Site(s):
 
Main Campus
Map and Directions
 
Contact: 800-600-3606 or info@ccadmin.wustl.edu
Description:
The purpose of this study is to determine the maximum tolerated dose and side effects of the combination of two drugs, temsirolimus and erlotinib, used to treat solid tumor cancers. Temsirolimus is approved by the Food and Drug Administration (FDA) for treatment of renal cancer and is considered investigational for this study. Erlotinib is FDA approved for non-small cell lung cancer and pancreatic cancer and is considered investigational for this study.
 
More Information:
ClinicalTrials.gov Entry
Internal Protocol Documents (requires Siteman administrative database password)